News

Press Releases

2023

Katairo announced topline results of the STARTT study.

2020

Katairo announces “Enrolement completed” in STARTT study of Remofuscin

2019

Katairo announces “First Patient Treated” in STARTT study of Remofuscin
Patienteninformation STARTT study Bonn
Patientinformation STARTT study Nijmegen and Leiden
Patienteninformation STARTT study Tuebingen
Patient Information STARTT study Southampton

2018

Stargardt-Krankheit: 6 Millionen für klinische Studie (German)
Katairo receives funding for STGD POC study

2017

Katairo licenses IP rights and data from Takeda

Information on clinical trials

Although Katairo is preparing a phase 2 trial for Stargardt disease, it is still too early to contact the company or its partners for more details. If you are interested in receiving up-to-date information by e-mail, please register for Katairo’s newsletter below.

Sign up for our newsletter!

For the purpose of being contacted by Katairo upon important news, you may provide your e-mail contact information below.

We use the external service Mailchimp to send our newsletter. When you submit the form, your data will be transferred to Mailchimp and processed there. You can unsubscribe from the newsletter at any time. See our privacy policy for more information.